A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Repare Therapeutics Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 351,000 shares of RPTX stock, worth $1.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
351,000
Previous 355,826 1.36%
Holding current value
$1.14 Million
Previous $2.6 Million 36.37%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$4.53 - $8.41 $21,861 - $40,586
-4,826 Reduced 1.36%
351,000 $1.65 Million
Q4 2023

Feb 13, 2024

BUY
$3.22 - $11.79 $653,421 - $2.39 Million
202,926 Added 132.72%
355,826 $2.6 Million
Q3 2023

Nov 14, 2023

BUY
$8.16 - $13.01 $57,120 - $91,070
7,000 Added 4.8%
152,900 $1.85 Million
Q2 2023

Aug 11, 2023

SELL
$8.63 - $12.53 $725,783 - $1.05 Million
-84,100 Reduced 36.57%
145,900 $1.54 Million
Q1 2023

May 12, 2023

BUY
$9.32 - $15.06 $620,712 - $1 Million
66,600 Added 40.76%
230,000 $2.26 Million
Q4 2022

Feb 13, 2023

BUY
$12.5 - $18.13 $353,487 - $512,698
28,279 Added 20.93%
163,400 $2.4 Million
Q3 2022

Nov 14, 2022

SELL
$11.57 - $15.59 $529,663 - $713,694
-45,779 Reduced 25.31%
135,121 $1.64 Million
Q2 2022

Aug 12, 2022

BUY
$8.45 - $14.84 $784,159 - $1.38 Million
92,800 Added 105.33%
180,900 $2.53 Million
Q1 2022

May 13, 2022

BUY
$11.38 - $21.88 $15,932 - $30,632
1,400 Added 1.61%
88,100 $1.26 Million
Q4 2021

Feb 11, 2022

BUY
$19.66 - $28.11 $1.37 Million - $1.96 Million
69,900 Added 416.07%
86,700 $1.83 Million
Q3 2021

Nov 12, 2021

SELL
$25.71 - $35.24 $92,556 - $126,864
-3,600 Reduced 17.65%
16,800 $441,000
Q2 2021

Aug 13, 2021

BUY
$30.1 - $34.85 $614,040 - $710,940
20,400 New
20,400 $636,000

Others Institutions Holding RPTX

About Repare Therapeutics Inc.


  • Ticker RPTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,937,800
  • Market Cap $136M
  • Description
  • Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that foc...
More about RPTX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.